PMID- 11274073
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20220310
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 42
IP  - 5
DP  - 2001 Apr
TI  - BDNF enhances retinal ganglion cell survival in cats with optic nerve damage.
PG  - 966-74
AB  - PURPOSE: To determine whether brain-derived neurotrophic factor (BDNF), a 
      neuroprotectant in the small rat eye, might also serve as an effective 
      neuroprotectant in larger vertebrate eyes. METHODS. A cat optic nerve crush model 
      was combined with standard histologic staining and analysis techniques. 
      Twenty-nine animals were studied, with the noninjected eye serving as the control 
      eye. RESULTS: No treatment, or intravitreal injection of sterile water, resulted 
      in an approximately 50% loss of ganglion cells 1 week after nerve crush. By 
      contrast, the mean percentages of surviving ganglion cells measured in eyes 
      receiving injections of 15, 30, 60, and 90 microg BDNF at the time of the nerve 
      damage were 52%, 81%, 77%, and 70%, respectively. Similar values were obtained 
      for ganglion cell density. Cell size measurements suggest a complex response 
      among the different classes of cat ganglion cells; 30 microg BDNF treatment 
      retained the highest number of large ganglion cells, whereas 90 microg minimized 
      the loss of medium-sized neurons and retained normal proportions of large, 
      medium, and small ganglion cells. CONCLUSIONS: The data show that BDNF is an 
      effective neuroprotectant in primate-sized eyes after optic nerve injury. 
      Although the amount required to achieve neuroprotection is much greater than that 
      needed for the small rat eye (30 microg versus 0.5 microg), when differences in 
      vitreal volume are considered, the effective dose is similar (0.01 microg 
      BDNF/microl vitreal volume). High doses of BDNF induce inflammation and result in 
      a decrease in total ganglion cell survival but appear necessary to save 
      medium-sized neurons, which are affected most severely by nerve injury.
FAU - Chen, H
AU  - Chen H
AD  - Department of Physiology, Michigan State University, East Lansing 48824, USA.
FAU - Weber, A J
AU  - Weber AJ
LA  - eng
GR  - EY11159/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*pharmacology
MH  - Cats
MH  - Cell Size
MH  - Cell Survival/*drug effects
MH  - Injections
MH  - Nerve Crush
MH  - Neuroprotective Agents/*pharmacology
MH  - Optic Nerve/surgery
MH  - Optic Nerve Injuries/complications/pathology
MH  - Retinal Degeneration/etiology/pathology/prevention & control
MH  - Retinal Ganglion Cells/*cytology/drug effects/metabolism
MH  - Retinal Vessels/drug effects/pathology
EDAT- 2001/03/29 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/03/29 10:00
PHST- 2001/03/29 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/03/29 10:00 [entrez]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2001 Apr;42(5):966-74.